Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan

Min‐Hua Tseng(Chang Gung Memorial Hospital), Chiu‐Ching Huang(China Medical University), I‐Jung Tsai(Apple (Israel)), Yeu‐Chin Chen(Tri-Service General Hospital), Wen‐Chien Chou(National Taiwan University), Min-Chih Chang(Mackay Memorial Hospital), Yee‐Hsuan Chiou(Kaohsiung Medical University), Jeng-Daw Tsai(Mackay Medical College), Kwan‐Dun Wu(University of Chicago), Shih‐Hua Lin(National Defense Medical Center)
Journal of the Formosan Medical Association
October 30, 2022
10.1016/j.jfma.2022.10.006
Cited by 18

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Kidney impairment in primary aldosteronism
|Clinica Chimica Acta|2011|133
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy
|Blood|2022|129
Case detection and diagnosis of primary aldosteronism – The consensus of Taiwan Society of Aldosteronism
|Journal of the Formosan Medical Association|2017|122
Risk of new-onset diabetes mellitus in primary aldosteronism
|Journal of Hypertension|2017|108